May 26
H. Jack West, MD: Another option in the first line setting for patients with advanced ALK+ NSCLC, though brigatinib… https://t.co/k9fEkGefkq

May 26
H. Jack West, MD: Elderly or frail patients did just as well on a reduced dose of erlotinib, with fewer adverse eff… https://t.co/qvJRVE5FyX

May 22
A recent FDA workshop delved into liquid biopsy screening approaches as they are increasingly being applied, partic… https://t.co/ZC83sOvoO2

May 21
H. Jack West, MD: While it's always nice to have another option, it's hard for me to see how atezolizumab provides… https://t.co/TUgQMgLwcA

May 21
Tomasz M. Beer, MD: PAPR inhibitor approval means that we will need to genotype all advanced prostate cancer patien… https://t.co/V0TnoRIDfR

May 20
At the #aacr2020 Virtual Meeting I, there was pivotal data from immunotherapy triplet trials in breast cancer, mela… https://t.co/eJ1m97OA6G

May 20
The emergence of #COVID-19 has transformed the care of cancer patients and upended the way practices do business. D… https://t.co/yLcc5dTpjn

May 19
At @oncologyCOA's first virtual conference, presenters discussed modernizing the clinical trial process, the comple… https://t.co/VIBVh1b8bA

May 19
Join us Tonight, May 19th 7:30 ET for a webinar discussing the unique management of advanced hepatocellular carcino… https://t.co/lgdd4xzlDb

May 19
H. Jack West, MD: I imagine that the nivolumab/ipilumumab combination will have some appeal to patients or physicia… https://t.co/faXlyOvMeC